Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of microfluidic systems specialist Fluidigm Corporation (FLDM -5.47%) popped 10% today after its quarterly results and outlook topped Wall Street expectations.
So what: The stock has rallied nicely in 2013 on strong operating momentum, and today's Q2 results -- loss narrowed to $1.7 million on a 35% revenue jump -- coupled with upbeat guidance only reinforce that trend. In fact, instrument revenue grew a whopping 47% year-on-year on robust demand for its C1 Single-Cell Auto Prep System, giving analysts plenty of good vibes over its adoption rates going forward.
Now what: Management now sees full-year revenue growth of 27%-31%, up nicely from an earlier view of 22%-26%.
"We have been increasingly successful in applied markets, where customers value high reproducibility, streamlined workflows, and lower running costs," said CEO Gajus Worthington. "Our growing customer base in this area spans agricultural biotechnology, biorepository, and clinical laboratory settings."
Of course, with the stock now up more than 50% from it 52-week lows and trading at a price-to-sales multiple of around 8, much of that growth might already be baked into the valuation.
